Could Oral Paclitaxel Plus Encequidar Be Offered as Outpatient mBC Treatment?
Gerardo Umanzor, MD, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 pandemic.
Gerardo Umanzor, MD, medical oncologist with Centro Oncologico Integral in San Pedro Sula, Honduras, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous (IV) formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 (COVID-19) pandemic.
In the phase 3 KX-ORAX-001 clinical trial (NCT02594371), progression-free survival (PFS) and overall survival (OS) improvement were achieved with the combination of oral paclitaxel plus encequidar versus intravenous paclitaxel plus encequidar. Umanzor says that considering the limitations of access to care during the pandemic, the idea of an outpatient treatment option is appealing for both physicians and patients.
A shift from IV infusions may also be a more cost-effective strategy for treating patients explains Umanzor, because inpatient care tends to be more costly compared with outpatient care.
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
